David M Duffy1. 1. Department of Medicine, Division of Dermatology, University of Southern California, Los Angeles, California, USA. info@drdavidmduffy.com
Abstract
BACKGROUND: Sclerotherapy is popular for the treatment of lower extremity telangiectasias and varicose and reticular veins. Although a large number of sclerosants are commonly employed, there are few data that directly compare their advantages and drawbacks. OBJECTIVES: To analyze and present the differences between sclerosants that make them more or less suitable agents in specific clinical applications. MATERIALS AND METHODS: A systemic review of published medical literature that compares and contrasts different classes of sclerosants is presented. RESULTS: There is no perfect sclerosant that is complication free and 100% effective. The ability to match the sclerosant to the clinical problem being approached makes the availability of more Food and Drug Administration-approved sclerosants appealing. CONCLUSION: Modern sclerosants that have been subjected to rigorous experimental and clinical trials will provide even more efficacious and safer patient treatments.
BACKGROUND: Sclerotherapy is popular for the treatment of lower extremity telangiectasias and varicose and reticular veins. Although a large number of sclerosants are commonly employed, there are few data that directly compare their advantages and drawbacks. OBJECTIVES: To analyze and present the differences between sclerosants that make them more or less suitable agents in specific clinical applications. MATERIALS AND METHODS: A systemic review of published medical literature that compares and contrasts different classes of sclerosants is presented. RESULTS: There is no perfect sclerosant that is complication free and 100% effective. The ability to match the sclerosant to the clinical problem being approached makes the availability of more Food and Drug Administration-approved sclerosants appealing. CONCLUSION: Modern sclerosants that have been subjected to rigorous experimental and clinical trials will provide even more efficacious and safer patient treatments.
Authors: Matheus Bertanha; Marcone Lima Sobreira; Carlos Eduardo Pinheiro Lúcio Filho; Jamil Victor de Oliveira Mariúba; Rafael Elias Farres Pimenta; Rodrigo Gibin Jaldin; Andrei Moroz; Regina Moura; Hamilton Almeida Rollo; Winston Bonetti Yoshida Journal: Trials Date: 2014-12-19 Impact factor: 2.279
Authors: Matheus Bertanha; Paula Angeleli Bueno de Camargo; Regina Moura; Winston Bonetti Yoshida; Rafael Elias Farres Pimenta; Jamil Victor de Oliveira Mariúba; Giovana Piteri Alcantara; Dênia Reis de Paula; Marcone Lima Sobreira Journal: Medicine (Baltimore) Date: 2016-09 Impact factor: 1.889